Benitec Biopharma Inc
For the period ended Jun 30, 2024. Filed Sep 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Sep 26, 2024
BNTC$9.28-6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Year Ended June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue: | ||
| Revenues from customers | $— | $75 |
| Operating expenses | ||
| Royalties and license fees | (108) | — |
| Research and development | 15,609 | 12,774 |
| General and administrative | 6,989 | 6,382 |
| Total operating expenses | 22,490 | 19,156 |
| Loss from operations | (22,490) | (19,081) |
| Other income (loss): | ||
| Foreign currency transaction gain (loss) | 40 | (415) |
| Interest income (expense), net | 904 | (33) |
| Other expense, net | (204) | (30) |
| Unrealized loss on investment | (1) | (3) |
| Total other income (loss), net | 739 | (481) |
| Net loss | $(21,751) | $(19,562) |
| Other comprehensive income (loss): | ||
| Unrealized foreign currency translation gain (loss) | (62) | 415 |
| Total other comprehensive income (loss): | (62) | 415 |
| Total comprehensive loss | $(21,813) | $(19,147) |
| Net loss | $(21,751) | $(19,562) |
| Deemed dividend | $(619) | — |
| Net loss attributable to common stockholders | $(22,370) | $(19,562) |
| Net loss per share: | ||
| Basic and diluted | $(5.51) | $(14.12) |
| Weighted-average shares outstanding: | ||
| Basic and diluted | 4,060,182 | 1,385,818 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.